Overview
- SHINE completed the acquisition of Lantheus’ SPECT business, taking over the North Billerica, Massachusetts manufacturing facility and a portfolio of diagnostic radiopharmaceuticals.
- TechneLite technetium-99m generators produced at the site for 55 years, along with Cardiolite, NEUROLITE, and Xenon Xe-133, support millions of imaging procedures across North America.
- The company says the deal adds immediate revenue and operational scale in a nuclear medicine market it pegs at $19 billion.
- SHINE’s Chrysalis facility in Janesville, Wisconsin remains under development to produce Mo-99 using fusion-based technology for a future integrated supply of Mo-99, Xe-133, and other isotopes.
- SHINE highlights existing therapeutic capacity with one of the largest Lu-177 operations in the western hemisphere, capable of up to 100,000 doses annually with potential expansion to 200,000.